Rights issue in Intervacc AB (SE) — SEK 104 million

Carnegie acted as sole global co-ordinator and bookrunner in the rights issue of SEK 100 million in Intervacc. Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work.